American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
China said on Saturday it strongly opposes Washington's decision to levy additional tariffs on $550 billion worth of Chinese goods and warned the United States of consequences...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
Federal Reserve Vice Chair Richard Clarida said Friday that the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
Recent trade friction between the two Asian powerhouses has morphed into a dispute with political implications that go far beyond the region.Asia Politicsread more
The deal will see Danaher pay $21 billion in cash, as well as assume certain GE pension liabilities.
The GE Life Sciences unit will join Danaher's Life Science as a stand-alone business. The GE biopharma unit is expected to generate about $3.2 billion in revenue this year. Danaher expects the deal to be complete by the fourth quarter.
GE shares traded as high as $11.75 a share in early trading before shedding some gains to close up 6.4 percent at $10.82 a share. Danaher's stock also jumped 8.5 percent to close at $123.15 a share.
"We are focused on completing the carve out [of the biopharma business] – which is 15 percent of the $20 billion healthcare segment – and focused on managing the remaining core business," GE Chairman and CEO Larry Culp told CNBC's Morgan Brennan.
Cowen Research said in a note to investors that this deal came at "a rich valuation that goes a long way towards GE's debt reduction."
"Sale of biopharma a positive," Credit Suisse said in a note. "Under CEO Culp, GE has been accelerating its strategy to strengthen and deleverage the balance sheet."
Additionally, GE announced plans to provide shareholders with its 2019 forecast on March 14.
Culp told CNBC that GE decided to break up the Life Sciences unit as the biopharma business is distinct from the pharmaceutical diagnostics business.
"IPO of healthcare was Plan A – but we got lots of inbound calls about this business and this is clearly a superior path," Culp told CNBC's David Faber.
Culp, who led Danaher for more than a decade, joined GE's board last February. Danaher approached GE with interest in acquiring the Life Sciences business last April, The Wall Street Journal reported, but GE did not pursue a deal. At the time, GE Chief Financial Officer Jamie Miller said GE had been attracting interest on some of its business units but was "looking to do deals that are smart for the company."
Under Culp, Danaher built its Life Sciences business into a major asset, which is now worth $6.5 billion. Culp was made GE Chairman and CEO in October, after GE's board of directors became frustrated with the pace of changes under former CEO John Flannery.
The deal's inclusion of some GE pension liabilities will be welcome news to investors. GE has hundreds of thousands of former and current employees covered by pension plans. At the end of 2018, pensions represented $21 billion of GE's $55 billion in industrial debt.
"We have too much debt," Culp said.
GE also on Monday closed the merger of its transportation business with Wabtec. GE received $2.9 billion in cash for the merger.